News round-up for 13-17 February by DDW Digital Content Editor Diana Spencer.
The drug discovery sector is feeling the love this Valentine’s week, with several new research collaborations bringing together a range of expertise and advanced bioinformatics, automation and artificial intelligence technologies to speed up the development of new treatments.
The top stories:
X-Chem and Kymera expand partnership to 12 targets
X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.
Partners use AI to speed up development of cancer therapies
AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.
Multimillion pound collaboration targets neurodegeneration
Astex Pharmaceuticals and The Medicines Discovery Institute, Cardiff University (MDI) have agreed a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases.
Automation for genomics could accelerate discovery
A collaboration between Automata and the Advanced Sequencing Facility (ASF) at The Francis Crick Institute hopes to unlock the power of integrated automation for genomics sample preparation.
Partners hope to “chart a new era of drug discovery”
A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments.